natgillin/translations-raw huggingface dataset:
Temozolomide SUN 250 mg hard capsules
Temozolomid SUN 250 mg tvrde kapsule
Very rare cases of lung side effects have been observed with Temozolomide SUN.
Pri primjeni Temozolomid SUN-a vrlo rijetko su primijećene nuspojave na plućima.
Propylene glycol Black iron oxide (E172)
šelak propilenglikol željezov oksid, crni (E172)
Temozolomide SUN 5 mg hard capsules
Temozolomid SUN 5 mg tvrde kapsule
- The other ingredients are: capsule content: lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose") capsule shell: gelatin, titanium dioxide (E171), sodium laurilsulfate printing ink: shellac, propylene glycol, yellow iron oxide (E172), blue #1/Brilliant Blue FCF Aluminium Lake (E133).
- Drugi sastojci su: sadržaj kapsule: laktoza, natrijev škroboglikolat, vrste B, tartaratna kiselina, stearatna kiselina (pogledajte dio 2 "Temozolomid SUN sadrži laktozu") ovojnica kapsule: želatina, titanijev dioksid (E171), natrijev laurilsulfat tinta za označavanje: šelak, propilenglikol, žuti željezov oksid (E172), Blue #1/Brilliant Blue
Ranbaxy Italia S.p.A. Viale Giulio Richard, 1 20143 Milano Italia tel. +39 02 33 49 07 93
20143 Milano Italia tel.
What Temozolomide SUN is and what it is used for What you need to know before you take Temozolomide SUN How to take Temozolomide SUN Possible side effects
Kako uzimati Temozolomid SUN Moguće nuspojave Kako čuvati Temozolomid SUN
Temozolomide SUN 140 mg hard capsules
Temozolomid SUN 140 mg tvrde kapsule
Temozolomide SUN 20 mg hard capsules temozolomide
Temozolomid SUN 20 mg tvrde kapsule temozolomid
Temozolomide SUN 250 mg hard capsules have a white opaque body and cap, imprinted in black ink.
Temozolomid SUN 250 mg tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s crnom tintom.
Temozolomide SUN 180 mg hard capsules
Temozolomid SUN 180 mg tvrde kapsule
Temozolomide SUN 20 mg hard capsules
Temozolomid SUN 20 mg tvrde kapsule
Temozolomide SUN 140 mg hard capsules temozolomide
Temozolomid SUN 140 mg tvrde kapsule temozolomid
Each hard capsule contains 20 mg temozolomide.
Jedna tvrde kapsula sadrži 20 mg temozolomida.
Temozolomide SUN 250 mg hard capsules temozolomide
Temozolomid SUN 250 mg tvrde kapsule temozolomid
Propylene glycol Red iron oxide (E172)
šelak propilenglikol željezov oksid, crveni (E172)
Temozolomide SUN 140 mg hard capsules have a white opaque body and cap, imprinted in blue ink.
Temozolomid SUN 140 mg tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s plavom tintom.
Each hard capsule contains 5 mg temozolomide.
Jedna tvrde kapsula sadrži 5 mg temozolomida.
Temozolomide SUN 5 mg hard capsules have a white opaque body and cap, imprinted in green ink.
Temozolomid SUN 5 mg tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute sa zelenom tintom.
Each hard capsule contains 140 mg temozolomide.
Jedna tvrde kapsula sadrži 140 mg temozolomida.
Temozolomide SUN 5 mg hard capsules temozolomide
Temozolomid SUN 5 mg tvrde kapsule temozolomid
At the start of Cycle 2, the dose is escalated to 200 mg/m2 if the CTC non-haematological toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/l, and the thrombocyte count is ≥ 100 x 109/l.
(osim za alopeciju, mučninu i povraćanje) te ako je apsolutni broj neutrofila (ABN) ≥ 1,5 x 109/l, a broj trombocita ≥ 100 x 109/l.
Each hard capsule contains 180 mg temozolomide.
Jedna tvrde kapsula sadrži 180 mg temozolomida.
Package Leaflet: Information for the user Temozolomide SUN 250 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 250 mg tvrde kapsule temozolomid
Summary of events reported with temozolomide in the post-marketing setting*
Nakon stavljanja lijeka u promet zabilježene su sljedeće dodatne ozbiljne nuspojave: Tablica 6. Sažetak štetnih događaja prijavljenih nakon stavljanja temozolomida u promet Infekcije i infestacije*
During the monotherapy phase, the dose and way you take Temozolomide SUN can vary.
Doza i način uzimanja Temozolomid SUN-a u fazi monoterapije razlikovat će se od prethodne faze.
Temozolomide SUN 100 mg hard capsules
Temozolomid SUN 100 mg tvrde kapsule
Temozolomide SUN 20 mg hard capsules have a white opaque body and cap, imprinted in yellow ink.
Temozolomid SUN 20 mg želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute sa žutom tintom.
Package Leaflet: Information for the user Temozolomide SUN 20 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 20 mg tvrde kapsule temozolomid
The body is imprinted with ‘100 mg' and two stripes.
Na tijelu je otisnuta oznaka '100 mg' i dvije crte.
Temozolomide SUN 180 mg hard capsules temozolomide
Temozolomid SUN 180 mg tvrde kapsule temozolomid
Neutropenia, thrombocytopenia, lymphopenia, leukopenia
trombocitopenija, anemija, leukopenija
Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired,
parestezije, poremećaj govora, tremor hemipareza, afazija, poremećaj ravnoteže, somnolencija, konfuzija, omaglica, narušeno pamćenje,
United Kingdom
United Kingdom tel.
Propylene glycol Yellow iron oxide (E172)
šelak propilenglikol željezov oksid, žuti (E172)
Package Leaflet: Information for the user Temozolomide SUN 5 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 5 mg tvrde kapsule temozolomid
Fever, asthenia, rigors, malaise, pain, taste perversion
vrućica, astenija, tresavica, slabost, bol, promjena osjeta okusa
Other special populations
Druge posebne populacije bolesnika Spol
Temozolomide SUN 100 mg hard capsules temozolomide
Temozolomid SUN 100 mg tvrde kapsule temozolomid
Package Leaflet: Information for the user Temozolomide SUN 180 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 180 mg tvrde kapsule temozolomid
Package Leaflet: Information for the user Temozolomide SUN 140 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 140 mg tvrde kapsule temozolomid
CTC Grade 2
Razina doze
Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/
L-Olanda/Nederland/Nederland/Niederlande/Países Baixos/
Cerebral haemorrhage, hypertension
gastroenteritis, hemoroidi
Hemiparesis, aphasia, balance impaired, somnolence, confusion, dizziness, memory impairment, concentration impaired, dysphasia,
somnolencija, afazija, poremećaj ravnoteže, omaglica, konfuzija, narušeno pamćenje, narušena koncentracija, neuropatija,
Temozolomide SUN 180 mg hard capsules have a white opaque body and cap, imprinted in red ink.
Temozolomid SUN 180 mg tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s crvenom tintom.
Imprint
PRILOG
Hard gelatin capsule, with white opaque cap and body, imprinted in yellow ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute sa žutom tintom.
Temozolomide SUN may make you feel tired or sleepy.
Upravljanje vozilima i strojevima Temozolomid SUN može uzrokovati umor ili pospanost.
Patients with newly-diagnosed glioblastoma multiforme
Bolesnici s novodijagnosticiranim multiformnim glioblastomom:
Temozolomide SUN 100 mg hard capsules have a white opaque body and cap, imprinted in pink ink.
Temozolomid SUN 100 mg tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s rozom tintom.
Package Leaflet: Information for the user Temozolomide SUN 100 mg hard capsules temozolomide
Uputa o lijeku: Informacije za korisnika Temozolomid SUN 100 mg tvrde kapsule temozolomid
Stomatitis, diarrhoea, dyspepsia, dysphagia, mouth dry
dispneja, kašalj dispneja, kašalj
TMZ dose levels for monotherapy treatment Dose level
Razine doze TMZ-a u fazi monoterapije
- The other ingredients are: capsule content: lactose, sodium starch glycolate (Type B), tartaric acid, stearic acid (see section 2 "Temozolomide SUN contains lactose") capsule shell: gelatin, titanium dioxide (E171), sodium laurilsulfate printing ink: shellac, propylene glycol, titanium dioxide (E171), blue #1/Brilliant Blue FCF Aluminium Lake (E133).
ovojnica kapsule: želatina, titanijev dioksid (E171), natrijev laurilsulfat tinta za označavanje: šelak, propilenglikol, titanijev dioksid (E171), Blue #1/Brilliant Blue FCF Aluminium Lake (E133).
EU/1/11/697/017 (5 hard capsules) EU/1/11/697/018 (20 hard capsules)
EU/1/11/697/017 (5 tvrdih kapsula) EU/1/11/697/018 (20 tvrdih kapsula)
Hard gelatin capsules, with white opaque cap and body, imprinted in blue ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s plavom tintom.
Hard gelatin capsules, with white opaque cap and body, imprinted in black ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s crnom tintom.
Stomatitis, diarrhoea,
neutropenija, trombocitopenija,
Hard gelatin capsules, with white opaque cap and body, imprinted in green ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute sa zelenom tintom.
Propylene glycol Red iron oxide (E172) Yellow iron oxide (E172) Titanium dioxide (E171)
šelak propilenglikol titanijev dioksid (E171)
Hard gelatin capsules, with white opaque cap and body, imprinted in red ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s crvenom tintom.
EU/1/11/697/015 (5 hard capsules) EU/1/11/697/016 (20 hard capsules)
EU/1/11/697/015 (5 tvrdih kapsula) EU/1/11/697/016 (20 tvrdih kapsula)
EU/1/11/697/023 (5 hard capsules) EU/1/11/697/024 (20 hard capsules)
EU/1/11/697/023 (5 tvrdih kapsula) EU/1/11/697/024 (20 tvrdih kapsula)
Name and address of the manufacturer responsible for batch release
PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet Sun Pharmaceutical Industries Europe BV
- the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
CTC stupanj nehematološke toksičnosti (osim alopecije, mučnine i povraćanja) CTC stupnja 2
EU/1/11/697/013 (5 hard capsules) EU/1/11/697/014 (20 hard capsules)
EU/1/11/697/013 (5 tvrdih kapsula) EU/1/11/697/014 (20 tvrdih kapsula)
EU/1/11/697/023 (5 capsules in blister) EU/1/11/697/024 (20 capsules in blister)
EU/1/11/697/023 (5 kapsula u blisteru) EU/1/11/697/024 (20 kapsula u blisteru)
EU/1/11/697/021 (5 hard capsules) EU/1/11/697/022 (20 hard capsules)
EU/1/11/697/021 (5 tvrdih kapsula) EU/1/11/697/022 (20 tvrdih kapsula)
EU/1/11/697/019 (5 hard capsules) EU/1/11/697/020 (20 hard capsules)
EU/1/11/697/019 (5 tvrdih kapsula) EU/1/11/697/020 (20 tvrdih kapsula)
Then, you will have 23 days without Temozolomide SUN.
Zatim slijede 23 dana bez uzimanja Temozolomid SUN-a, što čini ukupno 28 dana terapijskog ciklusa.
EU/1/11/697/017 (5 capsules in blister) EU/1/11/697/018 (20 capsules in blister)
EU/1/11/697/017 (5 kapsula u blisteru) EU/1/11/697/018 (20 kapsula u blisteru)
EU/1/11/697/021 (5 capsules in blister) EU/1/11/697/022 (20 capsules in blister)
EU/1/11/697/021 (5 kapsula u blisteru) EU/1/11/697/022 (20 kapsula u blisteru)
Weight decreased
Otisnuta oznaka
Opportunistic infections, including PCP
oportunističke infekcije, uključujući Pneumocystis jirovecii pneumoniju
EU/1/11/697/015 (5 capsules in blister) EU/1/11/697/016 (20 capsules in blister)
EU/1/11/697/015 (5 kapsula u blisteru) EU/1/11/697/016 (20 kapsula u blisteru)
EU/1/11/697/013 (5 capsules in blister) EU/1/11/697/014 (20 capsules in blister)
EU/1/11/697/013 (5 kapsula u blisteru) EU/1/11/697/014 (20 kapsula u blisteru)
EU/1/11/697/019 (5 capsules in blister) EU/1/11/697/020 (20 capsules in blister
EU/1/11/697/019 (5 kapsula u blisteru) EU/1/11/697/020 (20 kapsula u blisteru)
Visual field defect, vision blurred, diplopia
zamagljen vid ispad vidnog polja, zamagljen vid, diplopija
Visual acuity reduced, eye pain, eyes dry
bol u oku smanjena oštrina vida, bol u oku,
There is limited information in patients over 3 years of age who have taken Temozolomide SUN.
Informacije o primjeni Temozolomid SUN-a u djece starije od 3 godine su ograničene.
Endocrine disorders*
anoreksija anoreksija
MARKETING AUTHORISATION HOLDER
Tablični sažetak nuspojava
Very common (may affect more than 1 in 10 people): loss of appetite, headache, constipation
Vrlo česte (mogu se javiti u više od 1 na 10 osoba): gubitak teka, glavobolja, zatvor (otežano pražnjenje crijeva), mučnina (osjećaj mučnine), povraćanje, osip, gubitak kose, umor.
Your doctor will work out your exact dose.
Liječnik će izračunati točnu dozu Temozolomid SUN-a koja Vam je potrebna.
Hard gelatin capsules, with white opaque cap and body, imprinted in pink ink.
Tvrde želatinske kapsule s bijelom neprozirnom kapicom i tijelom, otisnute s rozom tintom.
MA (EU) number (Invented) name Strength Pharmaceutical Form
(Zaštićeno) ime Doza Farmaceutski oblik Put primjene Unutarnje pakovanje
ATCvet code: QI06AJ05.
ATCvet kod: QI06AJ05.
The reaction was transient.
Ta reakcija je bila prolazna.
Primary vaccination course: - first injection: from 8 weeks of age, - second injection: 3 to 4 weeks later.
Prvo cijepljenje: - prva injekcija: od 8. tjedana starosti, - druga injekcija: 3 do 4 tjedna kasnije.
Vaccination of FeLV positive cats is of no benefit.
Cijepljenje FeLV pozitivnih mačaka nije od koristi.
This vaccine should not be handled by persons who are immunodeficient or taking immunosuppressive medicinal products.
Ovim cjepivom ne smiju rukovati imunodeficijentne osobe ili osobe koje uzimaju imunosupresivne lijekove.
Use in healthy animals only.
Upotrijebiti samo na zdravim životinjama.
* less than 1 animal in 10,000 animals displaying adverse reaction(s) during the course of one treatment, including isolated reports.
* manje od 1 životinje na 10.000 životinja pokazalo je nuspojave tijekom jedne primjene , uključujući izolirane slučajeve.
EU/2/04/047/001 lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/047/002 lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/2/04/047/001 Liofilizat (10 bočica s 1 dozom) + otapalo (10 bočica od 1 ml) EU/2/04/047/002 Liofilizat (50 bočica s 1 dozom) + otapalo (50 bočica od 1 ml)
Per dose of 1 ml: Lyophilisate:
Po dozi od 1 ml: Liofilizat :
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podaci o neškodljivosti i djelotvornosti su dostupni, što je dokaz da ovo cjepivo smije biti primijenjeno istog dana, ali ne pomiješano s cjepivom protiv bjesnoće tvrtke MERIAL.
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
U normalnim uvjetima primjene, povremeno se mogu javiti apatija i anoreksija, kao i hipertermija (u trajanju obično 1 ili 2 dana).
Manufacturer responsible for the batch release: MERIAL
Nositelj odobrenja za proizvodnju odgovoran za puštanje proizvodne serije: MERIAL
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product.
Ne miješati s bilo kojim drugim veterinarsko-medicinskim proizvodom, osim otapalom za primjenu s proizvodom.
If self-injection occurs, immediate medical advice should be sought and the doctor informed that self-injection with a living chlamydial vaccine has occurred.
Ako dođe do samoinjiciranja, mora se odmah potražiti savjet liječnika, a liječnik mora biti obaviješten da je došlo do samoinjiciranja živim cjepivom protiv klamidije.
4.5 Special precautions for use Special precautions for use in animals
4.5 Posebne mjere za primjenu Posebne mjere predostrožnost za primjenu na životinjama
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
Soj cjepiva protiv mačje leukemije je rekombinant virusa boginja kanarinca koji izražava env i gag gene virusa FeLV-A.
No effect other than those already mentioned in section on “Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.
Nisu primijećene nikakve druge nuspojave osim onih spomenutih u odjeljku “Nuspojave” nakon primjene nekoliko doza, te hipertermije koja može izuzetno trajati 5 dana.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Preporučuje se provesti testiranje na virus FeLV prije cijepljenja.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
kaliciviroze, panleukopenije ili Chlamydophila (npr. kod mačića u dobi 9-12 tjedana porijeklom od mačaka cijepljenih prije graviditeta i/ili s poznatim ili suspektnim prethodnim izlaganjem patogenima), prvo cijepljenje treba odgoditi do dobi od 12 tjedana.
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Nakon rekonstitucije liofilizata s otapalom, injicirajte subkutano jednu dozu (1 ml) cjepiva, prema slijedećem rasporedu cijepljenja:
In very rare* cases, hyperthermia and lethargy sometimes associated with lameness has been observed one to three weeks following booster vaccination in adult cats.
U vrlo rijetkim slučajevima* primijećena je hipertermija i letargija ponekad povezana sa šepanjem jedan do tri tjedna nakon revakcinacije u odraslih mačaka.
In very rare cases, hyperthermia and lethargy sometimes associated with lameness has been observed one to three weeks following booster vaccination in adult cats.
U vrlo rijetkim slučajevima primijećena je hipertermija i letargija, ponekad povezana sa šepanjem jedan do tri tjedna nakon revakcinacije u odraslih mačaka.
Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis and feline leukaemia components and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Docjepljivanje: - prva revakcinacija mora se provesti za sve komponente jednu godinu nakon prvog cijepljenja, - naknadne revakcinacije moraju biti provedene svake godine za komponente klamidiozu i mačju leukemiju i u intervalima od najviše tri godine za komponente rinotraheitis, kalicivirozu, i panleukopeniju.
Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml of solvent, both closed with a butyl elastomer closure and sealed with an aluminium cap.
I staklena bočica s 1 ml otapala, obje zatvorene gumenim čepom i zapečaćeni aluminijskom kapicom.
Per dose of 1 ml: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50
Po dozi od 1 ml: FHV (soj F2) .................................................................................................................... ≥ 104,9 CCID50
The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis and feline leukaemia components.
Trajnost imuniteta nakon zadnje re-vakcinacije je 3 godine za komponente rinotraheitisa, kaliciviroze i panleukopenije i 1 godinu za komponente Chlamydophila felis i leukemiju mačaka.
Excipient:
Liofilizat :
Purevax RCPCh FeLV lyophilisate and solvent for suspension for injection
Purevax RCPCh FeLV liofilizat i otapalo za suspenziju za injekcije
Purevax RCPCh FeLV lyophilisate and solvent for suspension for injection.
Purevax RCPCh FeLV liofilizat i otapalo za suspenziju za injekcije.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate bottle
OSNOVNI PODACI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKOVANJA Bočica s liofilizatom
FeLV recombinant canarypox virus (vCP97)................................................................... ≥ 107.2 CCID50.
FeLV rekombiniran s virusom boginja kanarinca (vCP97) ............................................. ≥ 107,2 CCID50
Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis, feline panleucopenia virus and feline leukaemia virus.
Potiče aktivni imunitet protiv virusnog rinotraheitisa mačaka uzrokovanog herpes virusom, kaliciviroze mačaka, Chlamydophilia felis, panleukopenije mačaka i virusa mačje leukemije.
Gentamicin, at most .......................................................................................................................... 34 µg Solvent:
Gentamicin, najviše ......................................................................................................................... 34 µg Otapalo:
2 egg infective dose 50%.
1 količina virusa koja zarazi 50 posto stanica kulture u koju je dodan virus 2 količina virusa koja zarazi 50 posto oplođenih jaja u koja se virus ucijepi
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
- rijetke (više od 1 ali manje od 10 životinja na 10.000 životinja)
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Atenuirana Chlamydophila felis (soj 905) ......................................................................... ≥ 103,0 EID502 Atenuirani virus panleukopenije mačaka (PLI IV) ......................................................... ≥ 103,5 CCID501
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Pokazalo se da imunitet nastupa 1 tjedan nakon prvog cijepljenja protiv rinotraheitisa, kalicivirusa, Chlamydophila felis i panleukopenije,te 2 tjedna nakon prvog cijepljenja protiv leukemije mačaka.
Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate
Dinatrij hidrogen ortofosfat Monokalij fosfat anhidrid Natrijev klorid Dinatrij fosfat dihidrat Magnezij klorid heksahidrat Kacij klorid dihidrat
FeLV recombinant canarypox virus (vCP97) .................................................................. ≥ 107.2 CCID501 1 cell culture infective dose 50%
FeLV rekombiniran s virusom boginja kanarinca (vCP97) ............................................ ≥ 107,2 CCID501
Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent.
Pakovanje sadrži 10 bočica s 1 dozom liofilizata i 10 bočica s 1 ml otapala Pakovanje sadrži 50 bočica s 1 dozom liofilizata i 50 bočica s 1 ml otapala
Gentamicin, at most .......................................................................................................................... 34 µg
Gentamicin, najviše .......................................................................................................................... 34 µg